1-4 of 4
Sanjiv Modi, MD
Close
Sort by
Journal Articles

Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).

Roger M. Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Heidi McIntyre, Indra Fernando, Jay Backstrom, MD, C.L. Beach, PharmD
Journal: Blood
Blood (2007) 110 (11): 819.
https://doi.org/10.1182/blood.V110.11.819.819
Published: 2007
Journal Articles

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

Roger M. Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Heidi McIntyre, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH
Journal: Blood
Blood (2006) 108 (11): 2662.
https://doi.org/10.1182/blood.V108.11.2662.2662
Published: 2006
Journal Articles

Molecular Inhibition of mTOR with Temsirolimus (TORISEL™, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.

Sonali M. Smith, MD, Barbara Pro, MD, Scott Smith, MD, Patrick Stiff, MD, Eric Lester, MD, Sanjiv Modi, MD, Janet Dancey, MD, Everett E. Vokes, MD, Koen van Besien, MD
Journal: Blood
Blood (2006) 108 (11): 2483.
https://doi.org/10.1182/blood.V108.11.2483.2483
Published: 2006
Journal Articles

Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).

Roger Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Linda Lintz, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH
Journal: Blood
Blood (2005) 106 (11): 2517.
https://doi.org/10.1182/blood.V106.11.2517.2517
Published: 2005